



MagSense™ Technology

Early Detection of Cancer Through Targeted Imaging

ASX:IBX

DISCLAIMER



*This investor presentation (**Presentation**) has been prepared by Imagion Biosystems Limited (**Imagion** or the **Company**). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of Imagion or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Imagion or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.*

This presentation is not a Prospectus and contains summary information about Imagion and its activities, which is current as at the date of this presentation. The information included in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor should consider when making an investment decision. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Imagion and the impact that different future outcomes may have on Imagion. This presentation has been prepared without taking account of any person's investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, make their own assessment of the information and seek legal, financial, accounting and taxation advice appropriate to their jurisdiction in relation to the information and any action taken on the basis of the information. Imagion is an early stage medical technology company and has so far has not conducted research in human subjects.

The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. Unless required by applicable law or regulation, no person (including Imagion) is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, currency, accuracy, reasonableness or completeness of the information contained herein. Neither Imagion nor any other person (including its shareholders, directors, officers and employees) accepts any liability and Imagion, its shareholders, its related bodies corporate and their respective directors, officers and employees, to the maximum extent permitted by law, expressly disclaim all liabilities for any loss howsoever arising, directly or indirectly, from this presentation or its contents.

This presentation includes forward-looking statements that reflect Imagion's intentions, beliefs or current expectations concerning, among other things, Imagion's results of operations, financial condition, performance, prospects, growth, strategies and the industry in which Imagion operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors, many of which are beyond the control of Imagion. Imagion cautions you that forward-looking statements are not guarantees of future performance and that its actual results of operations, financial condition, performance, prospects, growth or opportunities and the development of the industry in which Imagion operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, Imagion does not guarantee any particular rate of return or the performance of Imagion nor does it guarantee the repayment or maintenance of capital or any particular tax treatment. Investors should note that past performance may not be indicative of results or developments in future periods and cannot be relied upon as an indicator of (and provides no guidance as to) Imagion's future performance. Imagion, its related bodies corporate and each of their respective directors, officers and employees and advisers expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements in this presentation or any change in Imagion's expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.

This presentation and any materials distributed in connection with this presentation are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about, and observe any such restrictions.



1 in 3 People are affected by Cancer

“Early detection of many diseases, particularly cancers, is key to successful treatment.”

“Despite technical advances in many areas of diagnostic radiology, the detection and imaging of human cancer remains poor. “

Chemical Reviews 2015 Nanoparticles in Medicine Vol 115


Journal of Clinical Oncology, 2008 New Technologies for Human Cancer Imaging Vol 26 No 24

THE BENEFITS OF EARLY DETECTION



Cost / Benefit ratio for early diagnosis provides better value than most drugs

IMPROVEMENT IN 5-YEAR SURVIVAL RATE...



To bring a drug to market:

- \$2.8 billion
- 13.5 years
- 96% probability of failure

Early diagnosis results in:

- 2-4x less cost
- Lower drug doses needed
- Avoidance of surgery
- Higher survival rates

IMPROVING DIAGNOSIS IN CANCER



Imagion has a platform technology that can improve diagnosis for many common cancers

BREAST CANCER

- Staging of metastatic HER2+ breast cancer eliminates lymphadenectomy for 50% of patients
- Detection of primary tumor would eliminate uncertainties from mammograms


OVARIAN CANCER

- Current standard of care requires “watchful waiting” by ultrasound
- Poor sensitivity of ultrasound results in late stage diagnosis

PROSTATE CANCER

- More than 1 million prostate biopsies done per year in U.S. alone

Multiple Clinical Targets



CLEAR UNMET MEDICAL NEED

50 years since last new imaging technology was introduced



Current technologies:

- Identify a “region of interest”
- Expose patients to radiation
- Require invasive biopsies to confirm
- Result in unnecessary biopsies

A NEW WAY TO DETECT CANCER

MagSense™ Technology will transform cancer diagnosis



MORE SENSITIVE

Better sensitivity than other imaging methods

Enabling earlier detection and treatment

SPECIFIC


Functional imaging that determines if cancer cells are present or not

SAFER

Does not expose patient to radiation and uses a bio-safe tracer agent

Minimizes the need for surgical or biopsy procedures reducing patient risk


Better sensitivity leads to earlier detection & more treatment options



HOW IT WORKS



Bio-safe magnetic nanoparticles are attracted to the tumor and detected



- Nanoparticles, specific for the cancer, bind to tumor cells
- Nanoparticles demagnetize or “relax” after exposure to a low magnetic field
- Nanoparticles attached to cancer cells “relax” more slowly than particles in circulation
- Ultra-sensitive detectors locate the presence of attached nanoparticles

DERISKING THE APPROVAL PROCESS

MagSense uses proven components & known principles



KNOWN MATERIALS

Iron oxide is already in use as contrast agent

Antibodies are standard for therapeutics & diagnostics

Safety profile has been affirmed as low risk by FDA

PROVEN TECHNOLOGIES


SQUID detectors are used in MEG/MCG systems

Coils are used in MRI with much higher magnetic fields


NOT REGULATED AS A DRUG

Clinical studies requiring fewer patients, saving cost

Patients will not require long-term monitoring



Cancer specific nanoparticle under development




Clinical instrument not yet developed and tested

COMPELLING BUSINESS MODEL




Proprietary consumable drives growth & profitability

ONE INSTRUMENT



MANY TESTS



PRINTER / INK REVENUE MODEL

*35% capacity utilization
\$2.2 million annual
revenue per instrument*

\$500K Capital Sale



\$1,500 / Test



50% Gross Margin


80% Gross Margin

Revenue through
licensing/partnership fees
Royalties or revenue share
on tests

STRONG R&D PIPELINE



Product Applications Under Development




* in collaboration with 3rd party

MILESTONES AND VALUATION DRIVERS



*Indicative development timeline and key inflection points**



- ❖ Toxicology Study provides safety profile and clears path to product manufacturing for use in humans.
- ❖ Clearance by regulatory authority and clinical site for First-In-Human study clears path.
- ❖ First-in-Human (FIH) study will provide indication of technology risk and clear the path to clinical and commercial development.
- ❖ Pivotal study provides path to regulatory clearance for commercialization.
- ❖ Deal with Commercial Partner or Licensee expected to include up front commercial rights fee and royalties on product sales.

* This development timeline is indicative only, and subject to change.

STRATEGIC PLAN

Path to future products & value



STAGING BREAST CANCER

Reduce unnecessary
surgery

\$700M

TUMOR DETECTION

Breast, prostate, lung
& ovarian

\$7B

MRI CONTRAST

Safer alternative to
current product,
Gadolinium

>\$3B

TREATMENT MONITORING

Monitor tumor size
and adjust treatment
accordingly

>\$2B

DOCTORS OFFICE

Hand-held MagSense
instrument

>\$14B

DETECTION & THERAPY

Provide both
detection & delivery
of therapy

>\$140B

Addressable Markets

EXPERIENCED TEAM



Core Strengths of Team

- ❖ Bringing medical devices to market
- ❖ Imaging technologies
- ❖ Clinical research and development
- ❖ Fundraising and capital markets
- ❖ Governance



ROBERT PROULX
CHAIRMAN & CEO

- Operationally oriented executive
- 25 years in life science & medical devices
- Product development & commercialization



JOHN HAZLE PHD
NON EXEC DIRECTOR

- Board certified in medical physics
- 30 years in pre-clinical & clinical imaging research
- Chairs Cancer Research at UT Graduate School of Biomedical Sciences



MICHAEL HARSH
NON EXEC DIRECTOR

- Former CTO of GE Healthcare
- 35 years in medical imaging product development



JOVANKA NAUMOSKA
NON EXEC DIR & COSEC

- Australian attorney with expertise in regulatory compliance, governance & risk management



BRONWYN LE GRICE
NON EXEC DIRECTOR

- 15 years in Australian commercial healthcare & technology markets



BRIAN CONN
CFO

- CFO for early & growth stage biotech
- 25 years raising both public & private capital & M&A



MARIE ZHANG PHD
VP R&D

- 20 years in drug development
- Leadership in early stage and startup founder



MARK VAN ASTEN
NON EXEC DIRECTOR

- Strong track record in diagnostics & healthcare
- 25 commercializing diagnostic products



DAVID LUDVIGSON
NON EXEC DIRECTOR

- 35 years in pharma, medical device
- Corporate strategy, M&A, & financing

INVESTMENT HIGHLIGHTS



LARGE OPPORTUNITY

\$100B cancer diagnostic market

Growing 7% annually

Medical imaging commands largest share

Under-addressed need for early diagnosis



UNIQUE TECHNOLOGY

New form of medical imaging

Molecularly specific & non-invasive

More sensitive than current methods

Protected by eight patents



COMMERCIAL STRATEGY

\$2B initial market focus

Applies to many types of cancer

Printer-ink revenue model

Potential for therapeutics & research markets



HIGHLY DE-RISKED

Technical feasibility demonstrated

Safety profile of technology vetted

Management & Board with track record bringing products to market



IMAGION BIOSYSTEMS

www.imagionbiosystems.com